The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Canntab Therapeutics Signs Joint Venture Agreement with Queensland Bauxite Subsidiary
Jan. 10, 2018 08:43AM PST
Cannabis Investing News
Canntab Therapeutics has recently entered into a joint venture agreement with VitaCann, a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL) in Australia.
Canntab Therapeutics has recently entered into a joint venture agreement with VitaCann, a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL) in Australia. The Finance News Network published a video segment regarding the news, highlighting that the companies are working towards having Canntab tablets approved for sale within the Australian market and for export to Asia.
This joint venture has positioned Canntab and its Australian partner favorably to expand production and manufacturing of the Medical Cannabis seed bank and products within the Australian market.
To watch the full video segment, click here.
Click here to connect with Canntab Therapeutics for investor information.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.